Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MZE829 in APOL1 Kidney Disease
NCT06830629Phase 2Recruiting
- Sponsor
- Maze Therapeutics
- Start
- Feb 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of MZE829 in chronic kidney disease (CKD), sponsored by Maze Therapeutics. Primary endpoint: Incidence of Adverse Events at 12 weeks. Started Feb 2025; status: recruiting.
02
Drugs
MZE829
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06830629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830629.